Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
RMPA-03 by Suzhou Raymon Pharmaceuticals for Pterygium: Likelihood of Approval
RMPA-03 is under clinical development by Suzhou Raymon Pharmaceuticals and currently in Phase II for Pterygium. According to GlobalData, Phase...